#South Korea #Seoul #Genomics #newborn screening #3billion

3billion's 3B-NEO: Transforming Newborn Genetic Screening

In a groundbreaking move poised to enhance proactive healthcare for newborns, 3billion, a leading AI-powered genomic diagnostics company, has announced the launch of 3B-NEO. This premium genomic newborn screening service enables healthcare providers to identify genetic risks associated with childhood-onset conditions before symptoms appear, facilitating timely medical intervention and improving patient outcomes.

A New Frontier in Newborn Health

3B-NEO is specifically designed to address a growing global demand for advanced genomic screening among healthcare providers. Unlike traditional newborn screening methods that mainly rely on biochemical markers and only evaluate a limited number of conditions, this service screens 595 carefully selected genes linked to serious genetic disorders that can manifest in early childhood. By focusing on actionable findings, 3B-NEO aims to empower physicians and families with crucial genetic insights that aid in clinical decision-making.

The panel includes genes associated with inherited metabolic disorders, immunologic disorders, neuromuscular diseases, and cardiovascular conditions, among others. By facilitating the early identification of genetic risks, 3B-NEO fosters quicker diagnosis and management, potentially leading to better health outcomes for affected children.

How It Works

Parents can access 3B-NEO through maternity hospitals, obstetric practices, and pediatric clinics. Designed for ease of implementation, healthcare providers can offer this service without needing to establish extensive in-house genomic testing infrastructure. Testing options include a standard Whole Exome Sequencing (WES) test and a premium Whole Genome Sequencing (WGS) test, with results typically delivered within about two weeks of sample receipt.

The Growing Need for Early Genetic Assessment

There is increasing clinical validation for genomic newborn screening worldwide, with large-scale pilot programs underway in regions like the United States and Europe. This momentum reflects a significant rise in demand for early genetic risk assessments that can guide healthcare strategies and interventions.

According to Changwon Keum, CEO of 3billion, “Genomic newborn screening creates the greatest value when it enables action before symptoms appear.” He emphasizes that the advancements in genomic medicine are increasingly allowing for the early identification of health risks, which is essential to mitigating the risk of irreversible complications in children.

Moving Forward with Precision Medicine

3billion has been at the forefront of genomic diagnostics since its founding in 2016, operating in over 75 countries and at more than 800 partner institutions globally. With the launch of 3B-NEO, the company is expanding its precision medicine strategy from addressing rare disease diagnosis to a more proactive model of genomic healthcare across various stages of life.

In conjunction with this launch, 3billion is establishing a U.S. subsidiary in Austin, Texas, thereby enhancing its operational capabilities in North America to better support healthcare providers and families in need of genetic testing solutions.

For further information about 3B-NEO and how it can benefit your healthcare approach, visit 3billion.io/neo and follow the company on social media platforms like LinkedIn and Instagram.

As genomic newborn screening is set to redefine pediatric healthcare, 3billion’s 3B-NEO is a pivotal step toward ensuring that children receive the best possible start in life through informed medical interventions based on actionable genetic insights.